University of California

Siamab Therapeutics, Inc.

Ajit Varki

Anna Maria Hedlund

Dzung Nguyen

Xi Chelsea Chen

Hai Yu

Wanqing Li

An Xiao

Andrea Koenig

Abhishek Santra

Lee-Ping Wang

Pam Tangvoranuntakul

Anoopjit Kooner

Nissi Varki

Elaine Muchmore

Pascal Gagneux

Richard B Schwab

Sandra Diaz

Vered Padler-Karavani

Barry E Rothenberg

Nancy Hurtado-Ziola

Richard Schwab

The present invention provides N-acetyl derivatives of sialic acids, including N-acetyl derivatives of Neu5Ac and Neu5Gc. Methods for preparing related precursors and a variety of sialosides are also disclosed.

N-acetylated sialic acids and related sialosides

The invention provides sialylated glycans and antibodies that specifically bind to them. The invention's compositions and methods for using them are useful for early detection and diagnosis of cancer.

Compositions and methods for detecting cancer

The application is in the field of transgenic (non-human) organisms, sialic acid chemistry, metabolism and antigenicity. More particularly, the invention is related to a method to produce Neu5Gc-free animals and products therefrom comprising disrupting the CMAH gene and thereby reducing or eliminating Neu5Gc from biological material of non-humans.

Elimination of N-glycolylneuraminic acid from animal products for human use

This application is in the field of sialic acid chemistry, metabolism, antigenicity, and the production of transgenic non-human mammals with altered sialic acid production. More particularly, this application relates to N-glycolylneuraminic acid (Neu5Gc) being an immunogen in humans, and the production of Neu5Gc-free mammalian products for laboratory and human use.

Transgenic mouse with a homozygous mutation in the CMAH gene

The present application is in the field of sialic acid chemistry, metabolism and antigenicity. More particularly, the present invention relates to the detection and analysis of the non-human sialic acid, N-glycolylneuraminic acid (Neu5Gc) in biological materials, such as food and clinical specimens. Such detection and analysis is facilitated by the use of Neu5Gc specific antibodies. The present invention also relates to the detection of antiNeu5Gc antibodies in clinical samples, as well as the production of anti-Neu5Gc specific antibodies.

Methods for detecting and analyzing N-glycolylneuraminic acid (Neu5Gc) in biological materials

The present application is in the field of sialic acid chemistry, metabolism and antigenicity. More particularly, the present invention relates to the detection and analysis of the non-human sialic acid, N-glycolylneuraminic acid (Neu5Gc) in bio-logical materials, such as food and clinical specimens. Such detection and analysis is facilitated by the use of Neu5Gc specific antibodies. The present invention also relates to the detection of anti Neu5Gc antibodies in clinical samples, as well as the production of anti-Neu5Gc specific antibodies.

The present invention provides methods of inhibiting L-selectin and P-selectin mediated binding in a subject by administering heparin to the subject in an amount that does not produce substantial anticoagulant activity or undesirable bleeding in the subject. In addition, the invention provides methods of treating a subject having a pathology characterized, at least in part, by abnormal L-selectin or P-selectin mediated binding by administering heparin to the subject in an amount that results in attaining a concentration of less than about 0.2-0.4 units heparin per ml of plasma in the subject.

Inhibition of L-selectin and P-selectin mediated binding using heparin

Inhibition of L-selectin and P-selection mediated binding using heparin

Fluorescent tagging compounds of the formula: ##STR1## wherein A is a member selected from the group consisting of an aromatic ring, a heteroaromatic ring, and a heterocyclic ring, and R is a linking moiety having from 1 to 20 carbon atoms, optionally containing nitrogen atoms, sulfur atoms, oxygen atoms, carbonyl groups, carboxyl groups, and/or amide groups, as well as fluorescent tagged oligosaccharide adducts derived therefrom are disclosed.

Growing community of inventors

La Jolla, CA, United States of America

Ajit Varki